Edition:
United States

Freeport-McMoRan Inc (FCX.N)

FCX.N on New York Stock Exchange

18.43USD
20 Feb 2018
Change (% chg)

$-0.30 (-1.60%)
Prev Close
$18.73
Open
$18.32
Day's High
$18.76
Day's Low
$18.29
Volume
4,155,482
Avg. Vol
4,968,388
52-wk High
$20.24
52-wk Low
$11.05

Select another date:

Mon, Feb 19 2018

Indonesia hands Freeport, Amman, quota for 2018 copper exports

* Indonesia issued the local unit of copper miner Freeport McMoRan Inc with a quota to export 1,247,866 wet metric tonnes (wmt) of copper concentrate up to Feb 15, 2019, a mining ministry official said on Monday.

BRIEF-Carl Icahn Now Owns 4.14 Pct Stake In Freeport-McMoRan

* CARL ICAHN SAYS NOW OWNS 4.14 PERCENT STAKE IN FREEPORT-MCMORAN INC AS OF FEB 14 - SEC FILING

Indonesia 'still evaluating' extension of Freeport copper exports -official

* Indonesia is 'still evaluating' a proposed extension of copper concentrate exports by local unit of Freeport McMoRan Inc , a mining ministry official said on Thursday.

Copper miner Freeport-McMoRan reinstates dividend on stronger outlook

Freeport-McMoRan Inc reinstated its cash dividend on Tuesday, three years after suspending it, reflecting a stronger financial position, improved market conditions and a positive outlook for cash generation.

Copper miner Freeport-McMoRan reinstates dividend on stronger outlook

Feb 6 Freeport-McMoRan Inc reinstated its cash dividend on Tuesday, three years after suspending it, reflecting a stronger financial position, improved market conditions and a positive outlook for cash generation.

BRIEF-Freeport-McMoRan Reinstates Cash Dividend On Common Stock

* FREEPORT-MCMORAN REINSTATES CASH DIVIDEND ON COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

Freeport points to progress in Indonesia permit talks

TORONTO Freeport-McMoRan Inc said it was edging closer to a permit deal with Indonesia for its massive Grasberg mine, but the world's second-biggest copper producer cautioned that it has not yet struck any formal agreements.

Select another date: